Literature DB >> 30281365

Dedifferentiated Liposarcoma With Myofibroblastic Differentiation.

Grace Y Wang, David R Lucas1.   

Abstract

CONTEXT.—: Liposarcoma is divided into myxoid, pleomorphic, well-differentiated, and dedifferentiated subtypes. Dedifferentiated liposarcoma displays the greatest histomorphologic diversity, including a subset with myofibroblastic differentiation that shares similarities with a spectrum of reactive, benign, and malignant soft tissue lesions. Misdiagnosis may lead to deleterious consequences, as dedifferentiated liposarcoma differs significantly in its prognosis and treatment from its mimics. OBJECTIVE.—: To review the clinicopathologic, immunohistochemical, and molecular features of the myofibroblastic variant of dedifferentiated liposarcoma as well as the key distinguishing features from its mimics. DATA SOURCES.—: Review of pertinent literature on major features and current understanding of dedifferentiated liposarcoma with myofibroblastic differentiation. CONCLUSIONS.—: The myofibroblastic variant of dedifferentiated liposarcoma is an uncommon and underrecognized sarcoma with several important differential diagnoses, and likely represents the major subset of aggressive retroperitoneal tumors that may have been misdiagnosed as desmoid-type fibromatosis, inflammatory myofibroblastic tumor, or another type of sarcoma in the past.

Entities:  

Mesh:

Year:  2018        PMID: 30281365     DOI: 10.5858/arpa.2018-0205-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001-2016.

Authors:  Suzanne Bock; Douglas G Hoffmann; Yi Jiang; Hao Chen; Dora Il'yasova
Journal:  Int J Environ Res Public Health       Date:  2020-04-15       Impact factor: 3.390

2.  Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.

Authors:  Liang Yan; Zhen Wang; Can Cui; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Xiuyun Tian; Chunyi Hao
Journal:  Cancer Sci       Date:  2019-08-29       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.